Crizotinib, the first and most completely characterized drug for treatment of these types of cancer, is an inhibitor of ALK, ROS1 and c-MET (Christensen et al., 2007) and exhibits robust activity in ALK fusion NSCLC patients, but treatment is complicated by the emergence of kinase domain point mutations and treatment resistance (Bosse and Maris, 2015; Hallberg and Palmer, 2013). Here, MET is linked to non-small cell lung carcinoma.